Keryx Biopharmaceuticals Inc. (KERX) is a Boston-based biopharmaceutical company working in the field of renal diseases.
The company’s only product is Auryxia (ferric citrate) which is marketed in the United States since 2014 for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In Sep 2015, Keryx gained EU approval for Fexeric (EU trade name for Auryxia) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adult patients with CKD, including dialysis and non-dialysis dependent CKD. Auryxia is also approved by the FDA to treat adults with iron deficiency anemia and CKD, not on dialysis. Keryx’s top line comprises license revenues and revenues earned from Auryxia sales.
Keryx’s earnings track record has been disappointing so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 25.57%.
Currently, Keryx has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Keryx’s first-quarter 2018 loss was narrower-than-expected. The company posted a loss of 18 cents per share narrower than consensus estimate of a loss of 19 cents.
Revenues: Revenues beat expectations. Keryx posted revenues of $21.7 million, abovethe consensus estimate of $21 million.
Key Stats: Auryxia net U.S. product sales came in at $20.6 million, up from $10.5 million in the year ago quarter. The increase was due to increase in Auryxia prescription and tablet demand,
Share Price Impact: The shares were down almost 0.8% in pre-market trading.
Check back later for our full write up on KERX earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Keryx Biopharmaceuticals Inc. (KERX) is a Boston-based biopharmaceutical company working in the field of renal diseases.
The company’s only product is Auryxia (ferric citrate) which is marketed in the United States since 2014 for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In Sep 2015, Keryx gained EU approval for Fexeric (EU trade name for Auryxia) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adult patients with CKD, including dialysis and non-dialysis dependent CKD. Auryxia is also approved by the FDA to treat adults with iron deficiency anemia and CKD, not on dialysis. Keryx’s top line comprises license revenues and revenues earned from Auryxia sales.
Keryx’s earnings track record has been disappointing so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 25.57%.
Currently, Keryx has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Keryx’s first-quarter 2018 loss was narrower-than-expected. The company posted a loss of 18 cents per share narrower than consensus estimate of a loss of 19 cents.
Revenues: Revenues beat expectations. Keryx posted revenues of $21.7 million, abovethe consensus estimate of $21 million.
Key Stats: Auryxia net U.S. product sales came in at $20.6 million, up from $10.5 million in the year ago quarter. The increase was due to increase in Auryxia prescription and tablet demand,
Share Price Impact: The shares were down almost 0.8% in pre-market trading.
Check back later for our full write up on KERX earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>